دورية أكاديمية
Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.
| العنوان: | Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. |
|---|---|
| المؤلفون: | Kartolo A; Department of Oncology, Queen's University, Kingston, ON K7L 2V7, Canada., Deluce J; Department of Oncology, University of Western Ontario, London, ON N6A 5W9, Canada., Hopman WM; Department of Public Health Sciences, Queen's University, Kingston, ON K7L 2V7, Canada., Liu L; Pulse Infoframe, London, ON N5X 4E7, Canada., Baetz T; Department of Oncology, Queen's University, Kingston, ON K7L 2V7, Canada., Ernst S; Department of Oncology, University of Western Ontario, London, ON N6A 5W9, Canada., Lenehan JG; Department of Oncology, University of Western Ontario, London, ON N6A 5W9, Canada. |
| المصدر: | Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Mar 01; Vol. 29 (3), pp. 1501-1513. Date of Electronic Publication: 2022 Mar 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Basel, Switzerland : MDPI Original Publication: Toronto : Multimed, c1994- |
| مواضيع طبية MeSH: | Melanoma*/drug therapy , Melanoma*/genetics , Melanoma*/pathology , Neoplasms, Second Primary* , Skin Neoplasms*/drug therapy , Skin Neoplasms*/genetics, Canada ; Humans ; Prospective Studies ; Proto-Oncogene Proteins B-raf/genetics ; Melanoma, Cutaneous Malignant |
| مستخلص: | Aim: To evaluate optimal systemic therapy sequencing (first-line targeted therapy (1L-TT) vs. first-line immunotherapy (1L-IO)) in patients with BRAF-mutated metastatic melanoma. Methods: Nation-wide prospective data of patients with newly diagnosed BRAF-mutated metastatic melanoma were retrieved from the Canadian Melanoma Research Network. Results: Our study included 79 and 107 patients in the 1L-IO and 1L-TT groups, respectively. There were more patients with ECOG 0−1 (91% vs. 72%, p = 0.023) in the 1L-IO group compared to the 1L-TT group. Multivariable Cox analysis suggested no OS differences between the two groups (HR 0.838, 95%CI 0.502−1.400, p = 0.500). However, patients who received 1L-TT then 2L-IO had the longest OS compared to 1L-IO without 2L therapy, 1L-IO then 2L-TT, and 1L-TT without 2L therapy (38.3 vs. 32.2 vs. 16.9 vs. 6.3 months, p < 0.001). For patients who received 2L therapy, those who received 2L-IO had a trend towards OS improvement compared with the 2L-TT group (21.7 vs. 8.9 months, p = 0.053). Conclusions: Our nation-wide prospective study failed to establish any optimal systemic therapy sequencing in advanced BRAF-mutant melanoma patients. Nevertheless, we provided evidence that immunotherapy has durable efficacy in advanced BRAF-mutant melanoma patients, regardless of treatment line, and that Canadian medical oncologists were selecting the appropriate treatment sequences in a real-world setting, based on patients’ clinical and tumour characteristics. |
| References: | Am J Clin Dermatol. 2020 Aug;21(4):493-504. (PMID: 32124332) N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635) J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33361337) N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847) Cancer Med. 2019 Dec;8(18):7637-7643. (PMID: 31677253) N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797) J Clin Oncol. 2019 Nov 20;37(33):3142-3151. (PMID: 31580757) Pathology. 2018 Dec;50(7):703-710. (PMID: 30348504) Target Oncol. 2019 Dec;14(6):729-742. (PMID: 31754963) Clin Cancer Res. 2021 Oct 1;27(19):5225-5235. (PMID: 34158360) Future Oncol. 2021 Feb;17(6):689-699. (PMID: 33084375) Future Oncol. 2019 Feb;15(5):459-471. (PMID: 30251550) J Immunother Cancer. 2016 Aug 16;4:44. (PMID: 27532019) Eur J Cancer. 2017 Sep;83:247-257. (PMID: 28756137) J Clin Oncol. 2020 Nov 20;38(33):3947-3970. (PMID: 32228358) N Engl J Med. 2019 Aug 15;381(7):626-636. (PMID: 31166680) Lancet. 2020 Jun 13;395(10240):1835-1844. (PMID: 32534646) Br J Cancer. 2013 May 28;108(10):2164-71. (PMID: 23579220) Lancet Oncol. 2019 Sep;20(9):1239-1251. (PMID: 31345627) Ann Oncol. 2020 Nov;31(11):1435-1448. (PMID: 32763453) Lancet Oncol. 2018 May;19(5):603-615. (PMID: 29573941) N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856) Cancer Immunol Immunother. 2019 May;68(5):765-772. (PMID: 30806748) J Clin Oncol. 2022 Jan 14;:JCO2101601. (PMID: 35030011) |
| فهرسة مساهمة: | Keywords: BRAF mutant; immunotherapy; melanoma; targeted therapy; therapy sequencing |
| المشرفين على المادة: | EC 2.7.11.1 (BRAF protein, human) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) |
| تواريخ الأحداث: | Date Created: 20220324 Date Completed: 20220414 Latest Revision: 20231213 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8947206 |
| DOI: | 10.3390/curroncol29030126 |
| PMID: | 35323326 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1718-7729 |
|---|---|
| DOI: | 10.3390/curroncol29030126 |